Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR Jr, Munshi N, Crawford ED.

N Engl J Med. 2001 Dec 6;345(23):1655-9.

2.

Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis.

Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED.

J Urol. 2004 Mar;171(3):1071-6.

PMID:
14767273
3.

Interferon alpha 2b as medical selection for nephrectomy in patients with synchronous metastatic renal cell carcinoma: a consecutive study.

Bex A, Kerst M, Mallo H, Meinhardt W, Horenblas S, de Gast GC.

Eur Urol. 2006 Jan;49(1):76-81. Epub 2005 Nov 2.

PMID:
16310929
4.

Cytokine therapy response as a selection criterion for cytoreductive nephrectomy in metastatic renal clear-cell carcinoma of intermediate prognosis. Results and conclusions from a combined analysis.

Bex A, Haanen JB, Vyth-Dreese FA, Horenblas S, de Gast GC.

Urol Int. 2008;80(4):367-71. doi: 10.1159/000132693. Epub 2008 Jun 27.

PMID:
18587246
5.

The timing of immunotherapy and nephrectomy in multimodality treatment of metastatic renal cell carcinoma.

Bex A, Horenblas S, de Gast GC.

Technol Cancer Res Treat. 2003 Jun;2(3):205-10. Review.

PMID:
12779351
6.

Cytoreductive nephrectomy in metastatic renal cancer.

Flanigan RC.

Curr Urol Rep. 2003 Feb;4(1):36-40. Review.

PMID:
12537937
7.

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ; Global ARCC Trial.

N Engl J Med. 2007 May 31;356(22):2271-81.

8.

[Survival of patients with advanced renal carcinoma treated with interferon].

Ares Valdés Y.

Arch Esp Urol. 2009 Jan-Feb;62(1):17-21. Spanish.

PMID:
19400442
9.

Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.

Vasselli JR, Yang JC, Linehan WM, White DE, Rosenberg SA, Walther MM.

J Urol. 2001 Jul;166(1):68-72.

PMID:
11435825
10.

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA.

N Engl J Med. 2007 Jan 11;356(2):115-24.

11.

Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.

Gollob JA, Rathmell WK, Richmond TM, Marino CB, Miller EK, Grigson G, Watkins C, Gu L, Peterson BL, Wright JJ.

J Clin Oncol. 2007 Aug 1;25(22):3288-95.

12.

Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study.

Pizzocaro G, Piva L, Colavita M, Ferri S, Artusi R, Boracchi P, Parmiani G, Marubini E.

J Clin Oncol. 2001 Jan 15;19(2):425-31.

PMID:
11208835
13.

Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma.

Pantuck AJ, Belldegrun AS, Figlin RA.

N Engl J Med. 2001 Dec 6;345(23):1711-2. No abstract available.

14.

Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group.

Ryan CW, Goldman BH, Lara PN Jr, Mack PC, Beer TM, Tangen CM, Lemmon D, Pan CX, Drabkin HA, Crawford ED; Southwest Oncology Group.

J Clin Oncol. 2007 Aug 1;25(22):3296-301.

15.

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.

Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R; European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group.

Lancet. 2001 Sep 22;358(9286):966-70.

PMID:
11583750
16.

Nephrectomy for metastatic renal-cell cancer.

Bolger G.

N Engl J Med. 2002 Apr 4;346(14):1095-6. No abstract available.

17.

Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).

Atzpodien J, Schmitt E, Gertenbach U, Fornara P, Heynemann H, Maskow A, Ecke M, Wöltjen HH, Jentsch H, Wieland W, Wandert T, Reitz M; German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group (DGCIN).

Br J Cancer. 2005 Mar 14;92(5):843-6.

18.

Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up.

Minasian LM, Motzer RJ, Gluck L, Mazumdar M, Vlamis V, Krown SE.

J Clin Oncol. 1993 Jul;11(7):1368-75.

PMID:
8315435
19.

Prognostic factors and the role of nephrectomy in metastatic renal cell carcinoma.

Uygur MC, Usubütün A, Ozen H, Ayhan A, Kendi S.

J Exp Clin Cancer Res. 1999 Sep;18(3):397-401. Review.

PMID:
10606187
20.
Items per page

Supplemental Content

Write to the Help Desk